Floatz logo

Zanzalintinib

Pancreatic Neuroendocrine Tumor (pNET)

ExelixisSmall moleculePhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
95/ 100

Competitive context

40 Active assets in the Pancreatic Neuroendocrine Tumor (pNET) cohort.

Asset / SponsorPhaseRating
Oxodotreotide
University of Chicago
Phase 4BBB
Everolimus
Exelixis
Phase 4BBB
Irinotecan
M.D. Anderson Cancer Center
Phase 2/3BB
Oxodotreotide
National Cancer Institute (NCI)
Phase 4BB
Octreotide Pamoate
RayzeBio, Inc.
Phase 3BB

View all 50 →

Same molecule, other indications

Zanzalintinib is also rated in:

renal cell carcinomaDormant
BB
Indicative ·
65 / 100
View asset →
hepatocellular carcinomaDormant
BB
Indicative ·
65 / 100
View asset →
Non-Clear Cell Renal Cell Carcinoma (nccRCC)Dormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →